Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide and Anavar (oxandrolone) are used for very different medical purposes, and combining them raises real clinical questions worth answering directly. Tirzepatide is a prescription-only weight-loss and diabetes medicine; oxandrolone is an anabolic steroid with its own prescription status and regulatory context in the UK. If you are currently using one and considering the other, or if you have seen both mentioned in weight-loss or bodybuilding spaces, the first thing to know is that these are not medicines to mix without talking to a prescriber first. Neither is available legally in the UK without a valid prescription following a clinical assessment, and the safety picture around combining them is not straightforward.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide works by activating two gut-hormone receptors simultaneously — GIP and GLP-1 — which together reduce appetite, slow gastric emptying and help the body regulate blood sugar. It is injected once a week using a pre-filled KwikPen and is the only dual-agonist weight-loss medicine licensed in the UK. The NHS medicines page for tirzepatide sets out its mechanism, licensed uses and known side-effect profile in detail.
Oxandrolone, sold under the brand name Anavar, is a synthetic anabolic steroid derived from testosterone. In a medical context it has occasionally been prescribed to preserve lean muscle during illness or recovery from severe burns, but it is not licensed or approved in the UK for weight management or body composition in healthy adults. It is a Class C controlled substance under the Misuse of Drugs Act 1971. That legal status is worth pausing on: importing or possessing it without a lawful prescription is a criminal offence, not simply a regulatory grey area.
People sometimes ask about combining the two because tirzepatide can reduce overall body weight fairly rapidly, and some want to preserve or build muscle alongside that loss. That is a reasonable concern, protecting lean mass during weight loss genuinely matters for long-term metabolic health. The problem is that reaching for an anabolic steroid to solve it introduces risks that are neither trivial nor well-studied in this specific combination.
There are no published clinical trials examining what happens when tirzepatide and oxandrolone are taken together. None. The SURMOUNT programme, which involved thousands of adults and generated the tirzepatide evidence base that NICE drew on in its appraisal (TA1026), excluded participants using anabolic steroids precisely because such substances confound weight, body composition and metabolic measurements.
What we do know separately is instructive. Oxandrolone is associated with significant hepatotoxicity (liver enzyme elevation is common with oral anabolic steroids) and tirzepatide itself affects gastric motility and can alter the absorption of other oral substances. Combining anything hepatotoxic with a medicine that changes gut transit is a conversation for a specialist, not a decision taken on the basis of forum posts. Oxandrolone also suppresses the body's natural testosterone production, affects lipid profiles (often reducing HDL cholesterol significantly), and can raise blood pressure. Each of those effects sits in territory where a prescriber needs a full picture before approving a weight-loss medicine alongside it.
There is also the straightforward point about supply. Anavar sold outside licensed medical channels is frequently counterfeit, contaminated or misdosed. The MHRA has repeatedly warned about unregulated substances in the performance-enhancement market, and the same enforcement logic that applies to fake weight-loss pens applies here.
The concern driving this question is understandable. Preserving muscle during weight loss is clinically worthwhile, and there is genuine evidence that GLP-1-class medicines can reduce some lean mass alongside fat. But the evidence-based responses to that are quite different from adding a controlled steroid.
Adequate protein intake (typically higher than people expect on a reduced appetite) matters. Resistance exercise has the strongest evidence base for preserving lean mass during any calorie deficit. Some people ask their prescriber about the titration pace, since slower dose increases tend to produce less abrupt appetite suppression and allow the body more time to adjust. These are the conversations to have with a prescriber and, where appropriate, a dietitian.
If you have a specific concern about muscle loss during treatment, the right step is to raise it at consultation. Our prescribers at nume look at the full clinical picture (not just weight and BMI) and that conversation is part of what a clinical review is for. You can read more about how tirzepatide works as a treatment and the questions most people bring to their first consultation.
For context on what treatment costs privately and what is included in a single transparent price, the background on Mounjaro pricing in the UK is worth reading before you compare providers.
If you are currently using oxandrolone (legally prescribed or otherwise) you must tell your prescriber before starting tirzepatide. This is not a formality. Liver function, lipid profile and blood pressure are all relevant to a safe prescribing decision, and a prescriber cannot assess those properly without the full picture. Omitting substances from your medication list does not make the risks go away; it just means they go unmanaged.
At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day you submit it. They review your medication list, your health history and your current circumstances before anything is approved. That review exists precisely for situations like this, where two substances interact in ways that need a trained clinical eye rather than a checklist. The prescriber's decision is always based on your individual profile, no algorithm makes that call.
If you have questions about how the process works or what to include in your consultation, the frequently asked questions cover the most common ones, and our team is available through the contact page seven days a week. You can also read about tirzepatide alongside HRT if that is also relevant to your situation, or how tirzepatide interacts with IBS for broader context on how gut motility matters to prescribing decisions. If you are living with a neurological condition, our guidance on using tirzepatide when you have MS illustrates how underlying health conditions shape prescribing decisions in ways worth understanding. Our clinical team and the prescriber leading our service, Mostafa Damghani, are named and verifiable. When you are ready to take the next step, start your free consultation and raise these questions directly with a prescriber. You can also explore tirzepatide dosing and pen options to understand the practical side of treatment before your first appointment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.